NEXT Financial Group Inc lowered its holdings in Celgene Co. (NASDAQ:CELG) by 40.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,280 shares of the biopharmaceutical company’s stock after selling 2,211 shares during the period. NEXT Financial Group Inc’s holdings in Celgene were worth $448,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in CELG. Iberiabank Corp grew its position in shares of Celgene by 7.5% in the second quarter. Iberiabank Corp now owns 10,901 shares of the biopharmaceutical company’s stock valued at $1,416,000 after purchasing an additional 764 shares during the period. Heritage Investors Management Corp purchased a new stake in shares of Celgene in the second quarter valued at $2,383,000. Capital Investment Advisors LLC grew its position in shares of Celgene by 16.6% in the second quarter. Capital Investment Advisors LLC now owns 2,791 shares of the biopharmaceutical company’s stock valued at $362,000 after purchasing an additional 397 shares during the period. New England Research & Management Inc. grew its position in shares of Celgene by 12.4% in the second quarter. New England Research & Management Inc. now owns 11,184 shares of the biopharmaceutical company’s stock valued at $1,452,000 after purchasing an additional 1,234 shares during the period. Finally, Fulton Bank N.A. grew its position in shares of Celgene by 4.0% in the second quarter. Fulton Bank N.A. now owns 25,623 shares of the biopharmaceutical company’s stock valued at $3,328,000 after purchasing an additional 996 shares during the period. 79.85% of the stock is owned by institutional investors and hedge funds.
Shares of Celgene Co. (CELG) opened at $102.02 on Thursday. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The firm has a market capitalization of $80,320.00, a PE ratio of 24.06, a PEG ratio of 0.67 and a beta of 1.77.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the business earned $1.58 earnings per share. The company’s revenue was up 10.2% compared to the same quarter last year. research analysts expect that Celgene Co. will post 6.7 EPS for the current fiscal year.
A number of research firms have issued reports on CELG. Royal Bank of Canada reissued a “buy” rating and set a $173.00 price target on shares of Celgene in a research report on Thursday, October 5th. Morgan Stanley downgraded Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research report on Thursday, October 5th. Robert W. Baird reissued a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Thursday, September 21st. Cantor Fitzgerald reissued a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Tuesday, September 26th. Finally, Vetr raised Celgene from a “hold” rating to a “buy” rating and set a $146.58 price target for the company in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $130.95.
WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/18/celgene-co-celg-stake-lowered-by-next-financial-group-inc.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.